PT2635601T - Anticorpos anti-il-23 - Google Patents
Anticorpos anti-il-23Info
- Publication number
- PT2635601T PT2635601T PT117819490T PT11781949T PT2635601T PT 2635601 T PT2635601 T PT 2635601T PT 117819490 T PT117819490 T PT 117819490T PT 11781949 T PT11781949 T PT 11781949T PT 2635601 T PT2635601 T PT 2635601T
- Authority
- PT
- Portugal
- Prior art keywords
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Obesity (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41015810P | 2010-11-04 | 2010-11-04 | |
| US41195310P | 2010-11-10 | 2010-11-10 | |
| US41259410P | 2010-11-11 | 2010-11-11 | |
| US201161448785P | 2011-03-03 | 2011-03-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT2635601T true PT2635601T (pt) | 2016-09-27 |
Family
ID=44936573
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT117819490T PT2635601T (pt) | 2010-11-04 | 2011-11-02 | Anticorpos anti-il-23 |
Country Status (39)
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3244B1 (ar) | 2009-10-26 | 2018-03-08 | Amgen Inc | ۚ۱ÙŰȘÙÙۧŰȘ ۱ۚ۷ Ù ŰłŰȘ۶ۧۯۧŰȘ il â 23 ۧÙۚێ۱ÙŰ© |
| PE20141162A1 (es) | 2010-11-04 | 2014-09-18 | Boehringer Ingelheim Int | Anticuerpos anti-il-23 |
| EP4039275A1 (en) * | 2012-05-03 | 2022-08-10 | Boehringer Ingelheim International GmbH | Anti-il-23p19 antibodies |
| AR094877A1 (es) * | 2013-03-08 | 2015-09-02 | Lilly Co Eli | Anticuerpos que se unen a il-23 |
| KR20150128859A (ko) | 2013-03-15 | 2015-11-18 | ìì ìžíŹ | í-il23 íìČŽë„Œ ìŹì©íìŹ íŹëĄ ëłì ìčëŁíë ë°©ëČ |
| EP2968488A1 (en) | 2013-03-15 | 2016-01-20 | Amgen Inc. | Methods for treating psoriasis using an anti-il-23 antibody |
| EP3172339A1 (en) * | 2014-07-24 | 2017-05-31 | Boehringer Ingelheim International GmbH | Biomarkers useful in the treatment of il-23a related diseases |
| UA123624C2 (uk) * | 2014-09-03 | 2021-05-05 | ĐŃĐŸŃŃĐœÒĐ”Ń ĐĐœÒДлŃŃ Đ°ĐčĐŒ ĐĐœŃĐ”ŃĐœĐ°ŃŃĐŸĐœĐ°Đ»Ń ÒĐŒĐ±Ń | ĐĄĐżĐŸĐ»ŃĐșĐ°, ŃпДŃĐžŃŃŃĐœĐ° ĐŽĐŸ ŃĐ»-23Đ° ŃĐ° ŃĐœĐż-Đ°Đ»ŃŃĐ°, ŃĐ° ŃŃ Đ·Đ°ŃŃĐŸŃŃĐČĐ°ĐœĐœŃ |
| CN107206081A (zh) * | 2015-02-04 | 2017-09-26 | ćææ Œæź·æ Œçż°ćœé æéć Źćž | æČ»ççæ§çŸç çæčæł |
| EP3283109A1 (en) | 2015-04-14 | 2018-02-21 | Boehringer Ingelheim International GmbH | Methods of treating diseases |
| IL256665B2 (en) | 2015-07-23 | 2023-10-01 | Boehringer Ingelheim Int | IL-23A Targeting Compound and B-Cell Activating Factor Nucleic Acids Encoding Them and Use of Products Containing Them |
| JP6909208B2 (ja) * | 2015-09-17 | 2021-07-28 | ăąă ăžă§ăł ă€ăłăłăŒăăŹă€ăăă | ïœïŒïŒç”è·Żăă€ăȘăăŒă«ăŒăäœżçšăăïœïœïŒïŒăąăłăżăŽăăčăă«ćŻŸăăèšćșćżçăźäșæžŹ |
| TWI811716B (zh) * | 2015-09-18 | 2023-08-11 | ćŸ·ćçŸéäœłæź·æ Œçż°ćéèĄä»œæéć Źćž | æČ»ççŒçæ§çŸç äčæčæł |
| EP3370768B9 (en) | 2015-11-03 | 2022-03-16 | Janssen Biotech, Inc. | Antibodies specifically binding pd-1 and their uses |
| AU2016379157A1 (en) | 2015-12-22 | 2018-06-21 | Amgen Inc. | CCL20 as a predictor of clinical response to IL23-antagonists |
| EP3560956A3 (en) | 2016-04-15 | 2020-01-01 | Boehringer Ingelheim International GmbH | Methods of treating inflammatory diseases |
| EP3526252A2 (en) | 2016-10-14 | 2019-08-21 | Boehringer Ingelheim International GmbH | Methods of treating diseases with il-23a antibody |
| WO2018119142A1 (en) | 2016-12-21 | 2018-06-28 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| US12398209B2 (en) | 2018-01-22 | 2025-08-26 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-PD-1 antibodies |
| AU2019215450A1 (en) * | 2018-02-05 | 2020-08-27 | Tesaro, Inc | Pediatric niraparib formulations and pediatric treatment methods |
| TWI837532B (zh) | 2018-03-30 | 2024-04-01 | çŸćçŸć犟äŸć€§è„ć» | æČ»ç朰çæ§ç”è žçäčæčæł |
| CA3105598A1 (en) | 2018-07-13 | 2020-01-16 | Carl GOMMOLL | Treating ulcerative colitis with brazikumab |
| CN110818793A (zh) * | 2018-08-14 | 2020-02-21 | äžć±±ćș·æčçç©ć»èŻæéć Źćž | æIL-1ÎČçæäœăć ¶èŻç©ç»ćç©ćć ¶çšé |
| CN109810947B (zh) * | 2019-01-18 | 2021-06-11 | ćäșŹèŽæ„çç©ç§ææéć Źćž | äžç§æć¶Th17ç»è掻ćçéŽć 莚ćčČç»èćć ¶ć¶ć€æčæłććșçš |
| WO2020212874A1 (en) * | 2019-04-15 | 2020-10-22 | Sun Pharma Global Fze | Methods for treatment of subjects with psoriatic arthritis |
| US12577297B2 (en) * | 2019-09-09 | 2026-03-17 | Boehringer Ingelheim International Gmbh | Anti-IL-23p19 antibody formulations |
| CA3164996A1 (en) * | 2019-12-20 | 2021-06-14 | Novarock Biotherapeutics, Ltd. | Anti-interleukin-23 p19 antibodies and methods of use thereof |
| CN111956606B (zh) * | 2020-08-31 | 2021-05-14 | æ±èè俥çç©ć»èŻæéć Źćž | ć ć«é«æ”ćșŠæäșșçœä»çŽ 23ćć éæäœçäœçČćșŠæ¶Čäœć¶ć |
| AR123477A1 (es) | 2020-09-10 | 2022-12-07 | Lilly Co Eli | Formulaciones de anticuerpos terapéuticos |
| TW202231292A (zh) * | 2020-10-13 | 2022-08-16 | çŸćć„ççç©ç§æć Źćž | çšæŒèȘżçŻććç°ïœïœćïŒæïœïœïœïœçç¶çç©ć·„çšæčé äčïœçŽ°èä»ć°äčć ç«ćăææăćć ¶ä»æčæł |
| JP2024521748A (ja) | 2021-05-28 | 2024-06-04 | ă€ăŒă©ă€ ăȘăȘăŒ ăąăłă ă«ăłăăăŒ | 朰çæ§ć€§è žçă«éąäžăăéșäŒćăźæïœïœïŒïŒïŒïœïŒïŒæäœèȘżçŻ |
| KR102761841B1 (ko) | 2021-07-09 | 2025-02-05 | ì°ìžëíê” ì°ííë „ëš | Il-23ì ìíŽ ë§€ê°ëë ì§íì ì€ìŠë ììžĄì© ìĄ°ì±ëŹŒ |
| WO2023056417A1 (en) | 2021-09-30 | 2023-04-06 | Eli Lilly And Company | Anti-il-23p19 antibody regulation of genes involved in bowel urgency in ulcerative colitis |
| WO2024077113A1 (en) | 2022-10-06 | 2024-04-11 | Eli Lilly And Company | Methods of treating fatigue in ulcerative colitis |
| CA3263219A1 (en) | 2022-10-21 | 2024-04-25 | Chong Kun Dang Pharmaceutical Corp. | STABLE ANTIBODY COMPOSITION |
| JP2026506184A (ja) | 2023-02-22 | 2026-02-20 | ă€ăŒă©ă€ ăȘăȘăŒ ăąăłă ă«ăłăăăŒ | 朰çæ§ć€§è žçă«ăăăéșäŒćăźèȘżçŻćăłăăźäœżçš |
| TW202511288A (zh) * | 2023-06-22 | 2025-03-16 | çŸć掟æćČĄé«çć Źćž | Il-23æé«ç”ćç©ćäœżçšæčæł |
| WO2025083549A1 (en) | 2023-10-16 | 2025-04-24 | Sun Pharma Advanced Research Company Limited | Methods and combinations of inhibitors of il-23 pathway and modulators of s1p signaling pathway for the treatment of autoimmune disorders |
| WO2025117506A1 (en) | 2023-11-29 | 2025-06-05 | Gilead Sciences, Inc. | Therapies for the treatment of inflammatory bowel disease |
| WO2025170982A2 (en) * | 2024-02-06 | 2025-08-14 | Paragon Therapeutics, Inc. | Il-23 antibody compositions and methods of use |
| WO2025171006A1 (en) * | 2024-02-06 | 2025-08-14 | Paragon Therapeutics, Inc. | Il-23 binding protein compositions and methods of use |
| CN117875575B (zh) * | 2024-03-12 | 2024-05-28 | äžćœç”ćç§æéćąć ŹćžçŹŹäșćäčç 究æ | äžç§ćșäșæ··ć仿ççźæłçćčČæ°è”æșćé æčæł |
| WO2026058045A1 (en) | 2024-09-12 | 2026-03-19 | Takeda Pharmaceutical Company Limited | Alpha4beta7 inhibitor and il-23 inhibitor combination therapy |
| WO2026060205A1 (en) | 2024-09-13 | 2026-03-19 | Eli Lilly And Company | PAN-ELR+ CXC CHEMOKINE ANTIBODIES AND IL-23p19 ANTIBODIES FOR THE TREATMENT OF ULCERATIVE COLITIS |
Family Cites Families (119)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4318980A (en) | 1978-04-10 | 1982-03-09 | Miles Laboratories, Inc. | Heterogenous specific binding assay employing a cycling reactant as label |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | ćłăźçŽ æ ȘćŒäŒç€Ÿ | 代çšèĄæ¶Č |
| WO1981001145A1 (en) | 1979-10-18 | 1981-04-30 | Univ Illinois | Hydrolytic enzyme-activatible pro-drugs |
| US4419446A (en) | 1980-12-31 | 1983-12-06 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA process utilizing a papilloma virus DNA as a vector |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| NZ201705A (en) | 1981-08-31 | 1986-03-14 | Genentech Inc | Recombinant dna method for production of hepatitis b surface antigen in yeast |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
| US4601978A (en) | 1982-11-24 | 1986-07-22 | The Regents Of The University Of California | Mammalian metallothionein promoter system |
| US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
| US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
| US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
| GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
| US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
| GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| GB8705477D0 (en) | 1987-03-09 | 1987-04-15 | Carlton Med Prod | Drug delivery systems |
| US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
| AU632065B2 (en) | 1988-09-23 | 1992-12-17 | Novartis Vaccines And Diagnostics, Inc. | Cell culture medium for enhanced cell growth, culture longevity and product expression |
| FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
| EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| WO1994004188A1 (en) | 1992-08-21 | 1994-03-03 | Genentech, Inc. | Method for treating an lfa-1-mediated disorder |
| MD1367C2 (ro) | 1992-11-13 | 2000-11-30 | Idec Pharmaceuticals Corporation | Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom. |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| US6037454A (en) | 1996-11-27 | 2000-03-14 | Genentech, Inc. | Humanized anti-CD11a antibodies |
| US5888809A (en) | 1997-05-01 | 1999-03-30 | Icos Corporation | Hamster EF-1α transcriptional regulatory DNA |
| PE20000183A1 (es) | 1997-07-25 | 2000-03-11 | Schering Corp | Citoquinas de mamiferos y reactivos relacionados |
| US6060284A (en) | 1997-07-25 | 2000-05-09 | Schering Corporation | DNA encoding interleukin-B30 |
| AU2661199A (en) | 1998-02-06 | 1999-08-23 | Schering Corporation | Mammalian receptor proteins; related reagents and methods |
| WO1999054357A1 (en) | 1998-04-14 | 1999-10-28 | Chugai Research Institute For Molecular Medicine, Inc. | Novel cytokine-like protein |
| CA2388562C (en) | 1999-09-09 | 2014-07-22 | Schering Corporation | Mammalian cytokines; related reagents and methods |
| US7090847B1 (en) | 1999-09-09 | 2006-08-15 | Schering Corporation | Mammalian cytokines; related reagents and methods |
| US7422743B2 (en) | 2000-05-10 | 2008-09-09 | Schering Corporation | Mammalian receptor protein DCRS5;methods of treatment |
| CA2408571C (en) | 2000-05-10 | 2014-04-29 | Schering Corporation | Mammalian receptor proteins; related reagents and methods |
| EP1449431A4 (en) | 2001-10-24 | 2007-11-28 | Chugai Pharmaceutical Co Ltd | SGRF-TRANSGENIC NON-MENTAL ANIMAL |
| JP5290489B2 (ja) | 2001-11-08 | 2013-09-18 | ăąăăŽăŁă»ăă€ăȘă»ă©ăă„ăŒăăŁăŻăčă»ă€ăłăłăŒăăŹă€ăăă | ïœïœæäœăźćźćźăȘæ¶Čäœć»èŹèŁœć€ |
| US7510709B2 (en) | 2002-10-30 | 2009-03-31 | Genentech, Inc. | Method of treating inflammatory disease by inhibition of IL-17 production |
| JP4902961B2 (ja) | 2002-12-23 | 2012-03-21 | ă·ă§ăŒăȘăłă° ăłăŒăăŹă€ă·ă§ăł | ćșäčłćç©ă”ă€ăă«ă€ăłăźçšéïŒéąéŁè©ŠèŹ |
| US20040219150A1 (en) | 2003-02-06 | 2004-11-04 | Cua Daniel J. | Uses of mammalian cytokine; related reagents |
| BRPI0408247A (pt) | 2003-03-10 | 2006-03-01 | Schering Corp | usos de antagonistas e agonistas de il-23 e reagentes relacionados |
| WO2005005612A2 (en) | 2003-07-01 | 2005-01-20 | University Of Virginia Patent Foundation | Tag-1 and tag-2 proteins and uses thereof |
| US8277810B2 (en) | 2003-11-04 | 2012-10-02 | Novartis Vaccines & Diagnostics, Inc. | Antagonist anti-CD40 antibodies |
| CA2544951A1 (en) | 2003-11-04 | 2005-05-19 | Chiron Corporation | Use of antagonist anti-cd40 monoclonal antibodies for treatment of multiple myeloma |
| PT1694360E (pt) | 2003-11-04 | 2010-12-13 | Novartis Vaccines & Diagnostic | Utilização de anticorpos monoclonais antagonistas anti-cd40 para o tratamento de doenças auto-imunes e inflamatórias e da rejeição ao transplante de orgãos |
| US20050100965A1 (en) | 2003-11-12 | 2005-05-12 | Tariq Ghayur | IL-18 binding proteins |
| AU2005215527B2 (en) | 2004-02-17 | 2011-04-07 | Merck Sharp & Dohme Corp. | Methods of modulating IL-23 activity; related reagents |
| CN1993480A (zh) | 2004-05-03 | 2007-07-04 | ć ç”ć Źćž | IlïŒ17èĄšèŸŸéąæ”çźè€ççççšéïŒæČ»çæčæł |
| US20050287593A1 (en) | 2004-05-03 | 2005-12-29 | Schering Corporation | Use of cytokine expression to predict skin inflammation; methods of treatment |
| US20060084145A1 (en) * | 2004-09-27 | 2006-04-20 | Anderson Glenn M | sRAGE mimetibody, compositions, methods and uses |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | Ù Ű±ÙۚۧŰȘ ŰŁŰŹŰłŰ§Ù Ù Ű¶Ű§ŰŻŰ© . |
| EP2292758A3 (en) | 2004-12-20 | 2013-12-25 | Merck Sharp & Dohme Corp. | Uses of mammalian cytokine; related reagents |
| AU2006265002B2 (en) * | 2005-06-30 | 2012-09-20 | Centocor, Inc. | Anti-IL-23 antibodies, compositions, methods and uses |
| CA2612785A1 (en) | 2005-06-30 | 2007-01-11 | Archemix Corp. | Polynucleotides and polypeptides of the il-12 family of cytokines |
| CN101248088A (zh) * | 2005-08-25 | 2008-08-20 | äŒè±ć©ć©ć Źćž | æil-23æäœ |
| DE602006015830D1 (de) * | 2005-08-25 | 2010-09-09 | Lilly Co Eli | Anti-il-23-antikörper |
| EP3190125A1 (en) | 2005-08-31 | 2017-07-12 | Merck Sharp & Dohme Corp. | Engineered anti-il-23 antibodies |
| PL1933869T3 (pl) | 2005-09-01 | 2010-06-30 | Merck Sharp & Dohme | Zastosowanie antagonistĂłw IL-23 i IL-17 do leczenia autoimmunologicznej zapalnej choroby oczu |
| EP1977007A4 (en) | 2005-12-28 | 2009-11-11 | Centocor Ortho Biotech Inc | MARKERS AND METHOD FOR THE ASSESSMENT AND TREATMENT OF PSORIASIS AND RELATED DISEASES |
| SI1971366T1 (sl) | 2005-12-29 | 2014-10-30 | Janssen Biotech, Inc. | Humana protitelesa anti-il-23, sestavki, postopki in uporabe |
| US7910703B2 (en) | 2006-03-10 | 2011-03-22 | Zymogenetics, Inc. | Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use |
| US20080311043A1 (en) | 2006-06-08 | 2008-12-18 | Hoffman Rebecca S | Uses and compositions for treatment of psoriatic arthritis |
| JP2009540018A (ja) | 2006-06-13 | 2009-11-19 | ă¶ă€ăąăžă§ăăăŁăŻăčïŒ ă€ăłăłăŒăăŹă€ăăă | ïœâïŒïŒăăăłïœïœâïŒïŒăąăłăżăŽăăčăăȘăăłă«ăăźäœżçšæčæł |
| CA2652924A1 (en) | 2006-06-19 | 2007-12-27 | Wyeth | Methods of modulating il-22 and il-17 |
| CA2674608A1 (en) | 2007-01-09 | 2008-07-17 | Wyeth | Anti-il-13 antibody formulations and uses thereof |
| TWI426918B (zh) | 2007-02-12 | 2014-02-21 | Merck Sharp & Dohme | ïœ-ïŒïŒæźæćæŒæČ»çææäčçšé |
| CN101605532A (zh) | 2007-02-16 | 2009-12-16 | æ æ°ć Źćž | ć«æć±±æąšçłéçèçœèŽšè°é ç© |
| AR065420A1 (es) | 2007-02-23 | 2009-06-03 | Schering Corp | Anticuerpos anti-il-23 p19 de ingenieria |
| EP2426145B1 (en) | 2007-02-23 | 2017-01-18 | Merck Sharp & Dohme Corp. | Engineered anti-il-23p19 antibodies |
| JP5337055B2 (ja) | 2007-02-28 | 2013-11-06 | ăĄă«ăŻă»ă·ăŁăŒăă»ăąăłăă»ăăŒă ă»ăłăŒăăŹăŒă·ă§ăł | ć ç«æ§éćźłăźćŠçœźăźăăăźç”ćăæČ»ç |
| PL2197903T3 (pl) | 2007-09-04 | 2015-03-31 | Us Gov Health & Human Services | Delecje w domenie ii egzotoksyny a psuedomonas zmniejszajÄ ce toksycznoĆÄ niespecyficznÄ |
| AR068723A1 (es) | 2007-10-05 | 2009-12-02 | Glaxo Group Ltd | Proteina que se une a antigenos que se une a il-23 humana y sus usos |
| EP2212442A1 (en) | 2007-10-26 | 2010-08-04 | Galderma Research & Development | Non-invasive method to perform skin inflammatory disease pharmaco-genomic studies and diagnosis method thereof |
| CA2607771A1 (en) | 2007-11-01 | 2009-05-01 | Her Majesty The Queen In Right Of Canada As Represented By The Minister Of National Defence | Humanized anti-venezuelan equine encephalitis virus recombinant antibody |
| TWI543768B (zh) | 2007-11-30 | 2016-08-01 | èŸäŒŻç¶çç©æèĄæéèČŹä»»ć Źćž | èçœèłȘèȘżé ç©ćèŁœé ć ¶äčæčæł |
| WO2009082624A2 (en) | 2007-12-10 | 2009-07-02 | Zymogenetics, Inc. | Antagonists of il-17a, il-17f, and il-23 and methods of using the same |
| MY153074A (en) | 2008-08-14 | 2014-12-31 | Teva Pharmaceuticals Australia Pty Ltd | Anti-il-12/11-23 antibodies |
| CA2734919C (en) | 2008-08-27 | 2016-08-16 | Schering Corporation | Lyophilized formulations of engineered anti-il-23p19 antibodies |
| US8420089B2 (en) | 2008-11-25 | 2013-04-16 | Alderbio Holdings Llc | Antagonists of IL-6 to raise albumin and/or lower CRP |
| CA2757237A1 (en) | 2009-04-01 | 2010-10-14 | Jane Elizabeth Clarkson | Anti-il-23 immunoglobulins |
| EP2414546A4 (en) | 2009-04-02 | 2013-03-13 | Univ Johns Hopkins | COMPOSITIONS AND METHODS FOR THE TREATMENT OR PREVENTION OF INFLAMMATORY DISEASE AND COLON CARCINOMA |
| US20120269765A1 (en) | 2009-07-24 | 2012-10-25 | Garcia K Christopher | Cytokine compositions and methods of use thereof |
| JO3244B1 (ar) | 2009-10-26 | 2018-03-08 | Amgen Inc | ۚ۱ÙŰȘÙÙۧŰȘ ۱ۚ۷ Ù ŰłŰȘ۶ۧۯۧŰȘ il â 23 ۧÙۚێ۱ÙŰ© |
| WO2011066374A2 (en) | 2009-11-24 | 2011-06-03 | Alder Biopharmaceuticals, Inc. | Antagonists of il-6 to prevent or treat cachexia, weakness, fatigue, and/or fever |
| CN102695465A (zh) | 2009-12-02 | 2012-09-26 | æŻćžæł°ć ć»çèĄä»œæéć Źćž | ç»ćć ·æćŻćèœŹæ±ćć€ćèæ±æçéȘšéćș件çć°èœźć»èæ±ćäœ |
| GB201013975D0 (en) | 2010-08-20 | 2010-10-06 | Imp Innovations Ltd | Method of treating desease |
| KR20130010461A (ko) | 2010-02-18 | 2013-01-28 | ëžëŠŹì€íš-ë§ìŽìŽì€ ì€í 컎íŒë | ïœâïŒïŒì êČ°í©íë íŒëžëĄë„íŽ êž°ë° ì€ìșíŽë ëë©ìž ëšë°±ì§ |
| BR112012021576A2 (pt) | 2010-02-26 | 2016-10-25 | Novo Nordisk As | composiçÔes eståveis contendo anticorpo. |
| US9956165B2 (en) | 2010-03-01 | 2018-05-01 | Cytodyn Inc. | Concentrated protein formulations and uses thereof |
| US20110318741A1 (en) | 2010-06-15 | 2011-12-29 | Schafer Peter H | Biomarkers for the treatment of psoriasis |
| US20110311527A1 (en) | 2010-06-16 | 2011-12-22 | Allergan, Inc. | IL23p19 ANTIBODY INHIBITOR FOR TREATING OCULAR AND OTHER CONDITIONS |
| EP2596022A4 (en) | 2010-07-20 | 2014-11-05 | Cephalon Australia Pty Ltd | SPECIFIC ANTIBODIES ANTI-HETERODIMER IL-23 |
| JP6173911B2 (ja) | 2010-09-10 | 2017-08-09 | ăĄăăŁăă„ăŒăł ăȘăăă | æäœèȘć°äœ |
| PE20141162A1 (es) | 2010-11-04 | 2014-09-18 | Boehringer Ingelheim Int | Anticuerpos anti-il-23 |
| GB201100282D0 (en) | 2011-01-07 | 2011-02-23 | Ucb Pharma Sa | Biological methods |
| TW201309330A (zh) | 2011-01-28 | 2013-03-01 | Abbott Lab | ć ć«çłćșćæé«äčç”ćç©ćć ¶çšé |
| WO2012104402A1 (en) | 2011-02-04 | 2012-08-09 | Ab Science | Treatment of severe persitent asthma with masitinib |
| EP4039275A1 (en) | 2012-05-03 | 2022-08-10 | Boehringer Ingelheim International GmbH | Anti-il-23p19 antibodies |
| ES2729603T3 (es) | 2012-06-27 | 2019-11-05 | Merck Sharp & Dohme | Anticuerpos IL-23 antihumanos cristalinos |
| KR20150128859A (ko) | 2013-03-15 | 2015-11-18 | ìì ìžíŹ | í-il23 íìČŽë„Œ ìŹì©íìŹ íŹëĄ ëłì ìčëŁíë ë°©ëČ |
| EP2968488A1 (en) | 2013-03-15 | 2016-01-20 | Amgen Inc. | Methods for treating psoriasis using an anti-il-23 antibody |
| KR20140119396A (ko) | 2013-03-29 | 2014-10-10 | ìŒì±ì ììŁŒìíìŹ | ëšë°±ì§ ìœëŹŒì ìĄì ì í |
| UA123624C2 (uk) | 2014-09-03 | 2021-05-05 | ĐŃĐŸŃŃĐœÒĐ”Ń ĐĐœÒДлŃŃ Đ°ĐčĐŒ ĐĐœŃĐ”ŃĐœĐ°ŃŃĐŸĐœĐ°Đ»Ń ÒĐŒĐ±Ń | ĐĄĐżĐŸĐ»ŃĐșĐ°, ŃпДŃĐžŃŃŃĐœĐ° ĐŽĐŸ ŃĐ»-23Đ° ŃĐ° ŃĐœĐż-Đ°Đ»ŃŃĐ°, ŃĐ° ŃŃ Đ·Đ°ŃŃĐŸŃŃĐČĐ°ĐœĐœŃ |
| CN107206081A (zh) | 2015-02-04 | 2017-09-26 | ćææ Œæź·æ Œçż°ćœé æéć Źćž | æČ»ççæ§çŸç çæčæł |
| IL256665B2 (en) | 2015-07-23 | 2023-10-01 | Boehringer Ingelheim Int | IL-23A Targeting Compound and B-Cell Activating Factor Nucleic Acids Encoding Them and Use of Products Containing Them |
| TWI811716B (zh) | 2015-09-18 | 2023-08-11 | ćŸ·ćçŸéäœłæź·æ Œçż°ćéèĄä»œæéć Źćž | æČ»ççŒçæ§çŸç äčæčæł |
-
2011
- 2011-11-02 PE PE2013000951A patent/PE20141162A1/es active IP Right Grant
- 2011-11-02 WO PCT/US2011/058869 patent/WO2012061448A1/en not_active Ceased
- 2011-11-02 SG SG2013031745A patent/SG190006A1/en unknown
- 2011-11-02 MX MX2013005015A patent/MX343858B/es active IP Right Grant
- 2011-11-02 GE GEAP201113106A patent/GEP201706733B/en unknown
- 2011-11-02 DK DK11781949.0T patent/DK2635601T3/en active
- 2011-11-02 SG SG10201604605VA patent/SG10201604605VA/en unknown
- 2011-11-02 BR BR112013011065-1A patent/BR112013011065B1/pt active IP Right Grant
- 2011-11-02 CN CN201180064083.5A patent/CN103282382B/zh active Active
- 2011-11-02 CN CN201710917166.3A patent/CN107522784B/zh active Active
- 2011-11-02 CA CA2816950A patent/CA2816950C/en active Active
- 2011-11-02 PH PH1/2013/500810A patent/PH12013500810B1/en unknown
- 2011-11-02 EP EP11781949.0A patent/EP2635601B1/en active Active
- 2011-11-02 LT LTEP11781949.0T patent/LT2635601T/lt unknown
- 2011-11-02 EA EA201890548A patent/EA201890548A1/ru unknown
- 2011-11-02 NZ NZ610592A patent/NZ610592A/en unknown
- 2011-11-02 SI SI201130958A patent/SI2635601T1/sl unknown
- 2011-11-02 CA CA3017116A patent/CA3017116A1/en not_active Abandoned
- 2011-11-02 KR KR1020187036509A patent/KR102049223B1/ko active Active
- 2011-11-02 EP EP17179739.2A patent/EP3281954A1/en not_active Withdrawn
- 2011-11-02 HR HRP20161141TT patent/HRP20161141T1/hr unknown
- 2011-11-02 KR KR1020137011474A patent/KR101931591B1/ko active Active
- 2011-11-02 PT PT117819490T patent/PT2635601T/pt unknown
- 2011-11-02 PL PL11781949T patent/PL2635601T3/pl unknown
- 2011-11-02 MX MX2019000046A patent/MX2019000046A/es unknown
- 2011-11-02 MY MYPI2013001519A patent/MY162791A/en unknown
- 2011-11-02 JP JP2013537771A patent/JP6126532B2/ja active Active
- 2011-11-02 AP AP2013006820A patent/AP3953A/en active
- 2011-11-02 RS RS20160762A patent/RS55161B1/sr unknown
- 2011-11-02 EA EA201300530A patent/EA030436B1/ru active Protection Beyond IP Right Term
- 2011-11-02 US US13/287,208 patent/US8778346B2/en active Active
- 2011-11-02 EP EP18188208.5A patent/EP3456740A1/en not_active Withdrawn
- 2011-11-02 ES ES11781949.0T patent/ES2593754T3/es active Active
- 2011-11-02 HU HUE11781949A patent/HUE030916T2/en unknown
- 2011-11-02 AU AU2011323426A patent/AU2011323426B2/en active Active
- 2011-11-02 MX MX2016015419A patent/MX362039B/es unknown
- 2011-11-02 EP EP16178404.6A patent/EP3115375A1/en not_active Withdrawn
- 2011-11-03 TW TW100140204A patent/TWI545133B/zh active
- 2011-11-03 AR ARP110104094A patent/AR083747A1/es active IP Right Grant
- 2011-11-03 TW TW105114183A patent/TWI653242B/zh active
- 2011-11-03 UY UY0001033703A patent/UY33703A/es active IP Right Grant
-
2012
- 2012-11-02 ME MEP-2016-176A patent/ME02499B/me unknown
-
2013
- 2013-04-09 IL IL225648A patent/IL225648A/en active Protection Beyond IP Right Term
- 2013-05-02 MA MA35866A patent/MA34641B1/fr unknown
- 2013-05-24 CO CO13128280A patent/CO6801628A2/es active IP Right Grant
- 2013-05-30 EC ECSP13012649 patent/ECSP13012649A/es unknown
-
2014
- 2014-06-12 US US14/302,986 patent/US9441036B2/en active Active
-
2016
- 2016-02-29 IL IL244335A patent/IL244335A/en active Protection Beyond IP Right Term
- 2016-08-04 US US15/228,254 patent/US10202448B2/en active Active
- 2016-09-13 CY CY20161100899T patent/CY1118014T1/el unknown
- 2016-12-16 AU AU2016273970A patent/AU2016273970B2/en active Active
-
2017
- 2017-01-13 JP JP2017003955A patent/JP6445596B2/ja active Active
-
2018
- 2018-09-24 AU AU2018236692A patent/AU2018236692C1/en active Active
- 2018-11-29 JP JP2018223469A patent/JP6758361B2/ja active Active
-
2019
- 2019-01-25 US US16/257,463 patent/US20190144534A1/en not_active Abandoned
- 2019-10-14 HU HUS1900048 patent/HUS1900048I1/hu unknown
- 2019-10-14 LU LU00132C patent/LUC00132I2/fr unknown
- 2019-10-15 LT LTPA2019518C patent/LTC2635601I2/lt unknown
- 2019-10-16 NL NL301013C patent/NL301013I2/nl unknown
- 2019-10-17 CY CY2019040C patent/CY2019040I1/el unknown
- 2019-10-17 NO NO2019038C patent/NO2019038I1/no unknown
-
2020
- 2020-10-09 US US17/066,994 patent/US20210198355A1/en not_active Abandoned
-
2024
- 2024-03-14 US US18/605,420 patent/US20250101093A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUS1900048I1 (hu) | Anti-IL-23 antitestek | |
| ZA201209004B (en) | Anti-fgfr2 antibodies | |
| GB201000467D0 (en) | Antibodies | |
| IL221371A0 (en) | Anti-lrp6 antibodies | |
| HUE040213T2 (hu) | Anti-TIM antitest | |
| HUE056313T2 (hu) | Anti-DLL3 antitest | |
| PL2616489T3 (pl) | PrzeciwciaĆo anty-huTNFR1 | |
| ZA201302459B (en) | Antibodies | |
| EP2596022A4 (en) | SPECIFIC ANTIBODIES ANTI-HETERODIMER IL-23 | |
| GB201103955D0 (en) | Antibodies | |
| GB201112056D0 (en) | Antibodies | |
| GB0920127D0 (en) | Antibodies | |
| GB0909906D0 (en) | Antibodies | |
| IL225667A0 (en) | A new antigen | |
| EP2565268A4 (en) | NEW MUC1 ANTIBODY | |
| GB201020738D0 (en) | Antibodies | |
| PT2603528T (pt) | Anticorpos glicosilados em fab | |
| EP2427496A4 (en) | ANTI-VEGF-D ANTIBODIES | |
| GB201002238D0 (en) | Antibodies | |
| GB0920324D0 (en) | Antibodies | |
| EP2499256A4 (en) | ANTI-C-MPL ANTIBODIES | |
| EP2714074A4 (en) | ANTIBODIES AGAINST EMR1 | |
| GB201007957D0 (en) | Antibody | |
| GB201020751D0 (en) | Antibodies | |
| GB201005062D0 (en) | Antibodies |